Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several li...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| シリーズ: | Annals of Oncology Research and Therapy |
| 主題: | |
| オンライン･アクセス: | https://journals.lww.com/10.4103/aort.aort_30_24 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|